Interactions between carbohydrates (glycans) on the surface of infectious disease pathogens or host cells are often essential drivers of disease processes. Our core strategy for countering infectious diseases is to first identify essential glyco-interactions using systems biology approaches (glycomics) and then to screen for inhibitors of these interactions using a high-throughput surface plasmon resonance (SPR) screen, combined with in silco approaches, to generate candidate inhibitors. A recent exemplar study identified an essential interaction between a glycosylation on the pili of the bacterial pathogen Neisseria gonorrhoeae and complement receptor 3 on human cervical epithelial cells. A library of 3,141 drugs and nutraceuticals was screened for binding to the human I-domain by SPR. We identified two drugs, carbamazepine and methyldopa, as effective host-targeted therapies for gonorrhea treatment. At doses below those currently used for their respective existing indications, both carbamazepine and methyldopa were more effective than ceftriaxone in curing cervical infection in ex vivo models of infection. This host-targeted approach would not be subject to N. gonorrhoeae drug resistance mechanisms. Thus, our data suggest a long-term solution to the growing problem of multidrug-resistant N. gonorrhoeae infections. This study, and other recent examples of repurposing drugs to target drug resistant infectious disease, will be presented.